Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  The Lancet

• Publication date

  2005-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(05)67482-XPMID 16198768
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.

  2004cited by this paper
• A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma

  2004cited by this paper
• Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?

  2004cited by this paper
• Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis.

  2004cited by this paper
• Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials.

  2003cited by this paper
• European approach to adjuvant treatment of intermediate- and high-risk malignant melanoma.

  2002cited by this paper
• Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials.

  2002cited by this paper
• The role interferon-alpha in malignant melanoma remains to be defined.

  2001cited by this paper
• High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.

  2001cited by this paper
• Adjuvant interferon alpha 2b in high risk melanoma – the Scottish study

  2001cited by this paper
• Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial.

  2001cited by this paper
• High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

  2000cited by this paper
• Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.

  1998cited by this paper
• Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group.

  1998cited by this paper
• Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases

  1998cited by this paper
• Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

  1996cited by this paper
• A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk

  1988cited by this paper

• The dual role of type I interferons in bacterial infections: from immune defense to pathogenesis

  2025cites this paper
• Challenges and opportunities of predicting overall survival benefit from improvements to recurrence-free survival in stage II/III melanoma: a correlation meta-analysis

  2025cites this paper
• Interferon alpha-2b (IFNα2b) in precision oncology: Innovations in delivery and combinatorial immunotherapy

  2025cites this paper
• The evolution of melanomology: a tale of giants' shoulders and bold hypotheses.

  2024cites this paper
• The immunogenic radiation and new players in immunotherapy and targeted therapy for head and neck cancer

  2023cites this paper
• Immunotherapy for metastatic melanoma—from little benefit to first-line treatment

  2023cites this paper
• Revisiting the melanomagenic pathways and current therapeutic approaches

  2022cites this paper
• European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022.

  2022cites this paper
• Adjuvant and Neoadjuvant Therapeutics for the Treatment of Cutaneous Melanoma.

  2021cites this paper
• Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis

  2021cites this paper
• Clinical Significance of Distant Metastasis-Free Survival (DMFS) in Melanoma: A Narrative Review from Adjuvant Clinical Trials

  2021cites this paper
• Novel adjuvant options for cutaneous melanoma.

  2021cites this paper
• Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials

  2021cites this paper
• Adjuvant therapy of malignant melanoma: general and practical experience

  2021cites this paper
• Characterization of Sentinel Lymph Node Immune Signatures and Implications for Risk Stratification for Adjuvant Therapy in Melanoma

  2020cites this paper
• Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial.

  2020cites this paper
• Systemic adjuvant therapy for adult patients at high risk for recurrent melanoma: A systematic review.

  2020cites this paper
• Adjuvant Systemic Therapy for High-Risk Melanoma Patients

  2020cites this paper
• Long Term Metastasis-Free Survival in Stage IV anal Melanoma Cured by Repetitive Surgery and Short Cycle of Adjuvant Ipilimubab

  2020cites this paper
• Adjuvant Therapy

  2019cites this paper
• Comparative efficacy and safety of dabrafenib in combination with trametinib versus competing adjuvant therapies for high-risk melanoma.

  2019cites this paper
• European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019.

  2019cites this paper
• Adjuvant Therapy for Melanoma

  2019cites this paper
• Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review

  2019cites this paper
• What's New in Pediatric Melanoma: An Update from the APSA Cancer Committee.

  2019cites this paper
• Upregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas

  2019cites this paper
• Adjuvant systemic therapy in high-risk melanoma.

  2019cites this paper
• Novel immunotherapies for metastatic melanoma - from mouse models towards clinical trials

  2019cites this paper
• Yeasts as Microbial Factories for Production of Recombinant Human Interferon Alpha 2b of Therapeutic Importance

  2019cites this paper
• Adjuvant and Neoadjuvant Treatment of Skin Cancer.

  2019cites this paper
• Novel glycosylated human interferon alpha 2b expressed in glycoengineered Pichia pastoris and its biological activity: N-linked glycoengineering approach.

  2019cites this paper
• An indirect treatment comparison of the efficacy of pembrolizumab versus competing regimens for the adjuvant treatment of stage III melanoma

  2019cites this paper
• Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.

  2019cites this paper
• Interferon-α versus interleukin-2 in Chinese patients with malignant melanoma: a randomized, controlled, trial

  2019cites this paper
• Polyethylene Glycol Nanoparticles as Promising Tools for Anticancer Therapeutics

  2019cites this paper
• Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial.

  2019cites this paper
• Melanoma: Immunotherapy in Advanced Melanoma and in the Adjuvant Setting

  2018cites this paper
• Lymph node ratio as a prognostic factor in melanoma: results from European Organization for Research and Treatment of Cancer 18871, 18952, and 18991 studies

  2018cites this paper
• Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

  2018cites this paper
• 13 Update on Clinical Trials for Malignant Melanoma

  2018cites this paper
• Interferon is associated with improved survival for node-positive cutaneous melanoma: a single-institution experience

  2018cites this paper
• Updates in adjuvant systemic therapy for melanoma

  2018cites this paper
• Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II–III Melanoma Adjuvant Therapy

  2018cites this paper
• Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges.

  2018cites this paper
• Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?

  2018cites this paper
• The avidity of tumor‐specific T cells amplified by a plasmacytoid dendritic cell‐based assay can predict the clinical evolution of melanoma patients

  2018cites this paper
• Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma.

  2018cites this paper
• (Neo)adjuvant systemic therapy for melanoma.

  2017cites this paper
• Update on adjuvant melanoma therapy

  2017cites this paper
• Dose-Escalation Study Evaluating Pegylated Interferon Alpha-2 a in Patients with Cutaneous T-Cell Lymphoma Running head : Pegylated IFN alpha-2 a in cutaneous T-cell lymphoma Names of authors :

  2017cites this paper
• Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis.

  2017cites this paper
• The efficacy and safety of adjuvant interferon-alfa therapy in the evolving treatment landscape for resected high-risk melanoma

  2017cites this paper
• Chapter 5 – Therapy of Melanoma

  2017cites this paper
• The Immunology of Melanoma.

  2017cites this paper
• Immune Checkpoint Inhibitors in Melanoma Define a New Era in Immunotherapy Aiming for Cure

  2017cites this paper
• Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma

  2017cites this paper
• Measuring the quality of melanoma surgery - Highlighting issues with standardization and quality assurance of care in surgical oncology.

  2017cites this paper
• Dose‐escalation study evaluating pegylated interferon alpha‐2a in patients with cutaneous T‐cell lymphoma

  2017cites this paper
• Malignant Melanoma in the Adolescent and Young Adult (AYA) Population

  2017cites this paper
• Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control.

  2017cites this paper
• Adjuvant Therapy for Melanoma

  2017cites this paper
• The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.

  2017cites this paper
• Long-term results of ultrasound guided fine needle aspiration cytology in conjunction with sentinel node biopsy support step-wise approach in melanoma.

  2017cites this paper
• Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette–Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study

  2017cites this paper
• An Update on Randomized Clinical Trials in Melanoma.

  2017cites this paper
• Immunotherapy in Melanoma

  2016cites this paper
• Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.

  2016cites this paper
• Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition).

  2016cites this paper
• Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade

  2016cites this paper
• Future perspectives in melanoma research

  2016cites this paper
• Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.

  2016cites this paper
• Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe – a systematic review of the literature

  2016cites this paper
• Diagnosis and treatment of melanoma . European consensus-based interdisciplinary guideline e Update 2016

  2016cites this paper
• Interferon Alpha Signalling and Its Relevance for the Upregulatory Effect of Transporter Proteins Associated with Antigen Processing (TAP) in Patients with Malignant Melanoma

  2016cites this paper
• Prognostic and predictive value of YKL-40 in stage IIB-III melanoma

  2016cites this paper
• Phase I study of pegylated interferon‐alpha‐2b as an adjuvant therapy in Japanese patients with malignant melanoma

  2016cites this paper
• Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma – Prima study

  2016cites this paper
• Adjuvant ipilimumab in stage III melanoma: New landscape, new questions.

  2016cites this paper
• Adjuvant treatment for stage III melanoma in the era of targeted medicine and immunotherapy.

  2016cites this paper
• Pediatric melanoma.

  2016cites this paper
• Adjuvant Therapy of Melanoma.

  2016cites this paper
• Risk Reductions of Recurrence and Mortality in Melanoma Patients Using IFN-α

  2016cites this paper
• Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition).

  2015cites this paper
• Who benefits most from adjuvant interferon treatment for melanoma?

  2015cites this paper
• The clinicopathological and gene expression patterns associated with ulceration of primary melanoma

  2015cites this paper
• Experiencia clínica en el tratamiento adyuvante de los pacientes con melanoma de tronco y extremidades estado III en un hospital del Tercer Mundo

  2015cites this paper
• The past, present and future of immunotherapy against tumor.

  2015cites this paper
• Interferon-α-2b as an adjuvant therapy prolongs survival of patients with previously resected oral muscosal melanoma.

  2015influential citation
• Immunology of Cutaneous Tumors and Immunotherapy for Melanoma

  2015cites this paper
• Cutaneous melanoma in Turkey: analysis of 1157 patients in the Melanoma Turkish Study.

  2015cites this paper
• Increased binding of circulating systemic lupus erythematosus autoantibodies to recombinant interferon alpha 2b

  2015cites this paper
• The use of interferon in melanoma patients: a systematic review.

  2015cites this paper
• Spanish Multidisciplinary Melanoma Group (GEM) guidelines for the management of patients with advanced melanoma

  2015cites this paper
• The long-term results and prognostic significance of cutaneous melanoma surgery using sentinel node biopsy with triple technique

  2015cites this paper
• Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.

  2015cites this paper
• Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies.

  2015cites this paper
• Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa

  2014cites this paper
• Immunotherapy of Cancer: Towards a New Era

  2014cites this paper
• Gender Differences in Melanoma Progression and Survival

  2014cites this paper
• Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors

  2014cites this paper